PMC:7534795 / 22487-22697 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T119","span":{"begin":141,"end":149},"obj":"Body_part"}],"attributes":[{"id":"A119","pred":"fma_id","subj":"T119","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"ssociated with improved clinical outcomes in patients with hyperinflammaory state (Ramiro et al., 2020)\n• Ruxolitinib treatment for elevated cytokine levels and inflammatory response • Prospective RCT\n• 18 to 7"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T39273","span":{"begin":203,"end":205},"obj":"http://purl.obolibrary.org/obo/CLO_0050510"}],"text":"ssociated with improved clinical outcomes in patients with hyperinflammaory state (Ramiro et al., 2020)\n• Ruxolitinib treatment for elevated cytokine levels and inflammatory response • Prospective RCT\n• 18 to 7"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T56","span":{"begin":161,"end":182},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"ssociated with improved clinical outcomes in patients with hyperinflammaory state (Ramiro et al., 2020)\n• Ruxolitinib treatment for elevated cytokine levels and inflammatory response • Prospective RCT\n• 18 to 7"}

{"project":"LitCovid-sentences","denotations":[{"id":"T157","span":{"begin":104,"end":200},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ssociated with improved clinical outcomes in patients with hyperinflammaory state (Ramiro et al., 2020)\n• Ruxolitinib treatment for elevated cytokine levels and inflammatory response • Prospective RCT\n• 18 to 7"}

{"project":"2_test","denotations":[{"id":"33031856-32719045-84038850","span":{"begin":98,"end":102},"obj":"32719045"}],"text":"ssociated with improved clinical outcomes in patients with hyperinflammaory state (Ramiro et al., 2020)\n• Ruxolitinib treatment for elevated cytokine levels and inflammatory response • Prospective RCT\n• 18 to 7"}

{"project":"LitCovid-PubTator","denotations":[{"id":"661","span":{"begin":45,"end":53},"obj":"Species"}],"attributes":[{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"Tax:9606"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ssociated with improved clinical outcomes in patients with hyperinflammaory state (Ramiro et al., 2020)\n• Ruxolitinib treatment for elevated cytokine levels and inflammatory response • Prospective RCT\n• 18 to 7"}